India has detected forty-eight cases of Delta plus variant across 11 states, with Maharashtra reporting 20 such cases followed by seven infections in Madhya Pradesh on Friday.
The government has said the Delta plus variant is localised with a limited number of cases in the world, and laboratory studies are on to study the efficacy of vaccines against this variant.
“This virus has been isolated and we should have the results of the effect of the vaccine on the Delta plus variant in about a week. We will be the first country to do so,” said Balram Bhargava, director-general, Indian Council of Medical Research.
Bhargava said Covaxin’s efficacy against Aplha, Beta, Delta is “very much there” and public health response strategy does not change with variants. “If required, vaccine composition can be changed according to variants,” he said.
The INSACOG with its network of 28 labs is collecting samples from 300 sites across the country. The INSACOG is also sequencing samples of reinfection, severe cases, and breakthrough infections after the vaccination from hospitals.
“We are sharing information on this variant regularly with the states. They are advised to keep strict surveillance in the districts reporting new Variants of Concern and take up stringent public health measures,” said Sujeet Singh, director, National Centre for Disease Control.
The Delta Plus, or Delta-AY.1 variant, a sub-lineage of Delta variant, is a mutated version of the B.1.617.2 variant or strain. This strain is characterised by the K417N mutation in the spike protein of the SARS-CoV2 virus that causes the Covid-19 disease. The K417N mutation has been associated with “immune escape”, which means that the virus is less susceptible to — or less responsive to — any drug therapy.
The government has said the Delta plus variant is localised with a limited number of cases in the world, and laboratory studies are on to study the efficacy of vaccines against this variant.
“This virus has been isolated and we should have the results of the effect of the vaccine on the Delta plus variant in about a week. We will be the first country to do so,” said Balram Bhargava, director-general, Indian Council of Medical Research.
Bhargava said Covaxin’s efficacy against Aplha, Beta, Delta is “very much there” and public health response strategy does not change with variants. “If required, vaccine composition can be changed according to variants,” he said.
The INSACOG with its network of 28 labs is collecting samples from 300 sites across the country. The INSACOG is also sequencing samples of reinfection, severe cases, and breakthrough infections after the vaccination from hospitals.
“We are sharing information on this variant regularly with the states. They are advised to keep strict surveillance in the districts reporting new Variants of Concern and take up stringent public health measures,” said Sujeet Singh, director, National Centre for Disease Control.
The Delta Plus, or Delta-AY.1 variant, a sub-lineage of Delta variant, is a mutated version of the B.1.617.2 variant or strain. This strain is characterised by the K417N mutation in the spike protein of the SARS-CoV2 virus that causes the Covid-19 disease. The K417N mutation has been associated with “immune escape”, which means that the virus is less susceptible to — or less responsive to — any drug therapy.

)